Overview

Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011

Status:
Completed
Trial end date:
2018-05-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the PK and safety profile of LEE011 following a single oral dose in adult subjects with various degrees of renal impairment compared to a matched group of healthy subjects with normal renal function.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals